News

Ofev effectiveness, safety seen over 3-year SENSCIS extension trial

Treatment with Ofev (nintedanib) for up to four years was associated with a sustained slowing of lung function decline in people with systemic sclerosis (SSc) associated with interstitial lung disease (SSc-ILD). That’s according to new results from the open-label study SENSCIS-ON (NCT03313180), a three-year extension of the…

Poor sleep in scleroderma linked to inadequate sleep hygiene: Study

People with systemic sclerosis (SSc) face significantly worse sleep quality than those with rheumatoid arthritis (RA) and healthy people, a study reports. Poor sleep hygiene and clinical factors, including gastroesophageal reflux disease, that is, acid reflux, and depression-like symptoms, were key contributors. These findings highlight how “enhancing sleep hygiene…

Immunosuppressants may help treat scleroderma with heart involvement

Immunosuppressive medications may help to reduce inflammation in the heart and the overall burden of primary heart involvement that is associated with systemic sclerosis (SSc), a retrospective study suggests. Larger studies are needed to confirm these findings, its researchers stated. The study, “Immunosuppressive therapy to treat newly diagnosed…

Autotaxin protein found at higher levels in women with SSc-ILD

Autotaxin, a protein involved in wound healing and scarring, or fibrosis, was found at higher levels in women with systemic sclerosis-associated interstitial lung disease (SSc-ILD) than in men with the condition, per a new U.S. study. According to the researchers, “this study is the first to report sex-specific ……